1500030000165003300016500330001800036000
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)

1500030000165003300016500330001800036000
5T/box(Ⅰ-01)10T/box(Ⅰ-02)5T/box(Ⅱ-01)10T/box(Ⅱ-02)5T/box(Ⅲ-01)10T/box(Ⅲ-02)5T/box(Ⅳ-01)10T/box (IV-02)
Mayo Consensus Guidelines for Myeloma Stratification and Risk-Adapted Therapy (mSMART) in the United States: Detection of relevant marker abnormalities by FISH for myeloma risk classification, different treatment regimen development, and risk assessment in primary diagnosis of multiple myeloma MM and relapsed MM;
NCCN MM 2013, version 1: Bone marrow examination in the initial diagnosis of different patients should include routine chromosomal karyotyping and fluorescence in situ hybridization testing of plasma cells obtained by bone marrow aspiration. Markers include t(4;14), t(14;16), 17p13 deletion, t(11;14), chromosome 13 deletion, and chromosome 1 amplification.